Clinical trial · Interventional
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer
A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Metabolic Medicines for the Treatment of Cancer Compared Against Matched Controls
NCT02201381CI-TRIAL-00059690METRICSwithdrawnPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Prospective recruitment not possible
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree of response and changes in biochemical markers (such as glucose and lipid levels).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Overall Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metabolic treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metabolic Treatment
- description
- Subjects will take the following treatments and have their data collected from their medical records every 3 months. * Oral atorvastatin up to 80mg uid, for study duration. * Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration. * Oral doxycycline 100mg uid, for study duration. * Oral Mebendazole 100mg uid, for study duration.
- interventionNames
- Drug: Metabolic treatment
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- up to 5 years
- description
- Overall survival for all cancer types and for each cancer type (years and months)
Secondary outcomes (4)
- measure
- Change in primary tumour size cancer types and by cancer type.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion criteria 1. Male or female 18-85 years old; 2. Diagnosed with cancer and have had such diagnosis confirmed by scan, blood markers and/or biopsy; 3. Is receiving or will shortly receive standard of care therapy or has completed standard of care treatment; and 4. Signed and dated written informed consent from the participant or LAR. Exclusion Criteria: 1. Pregnant or lactating females or females who are planning a pregnancy during the course of the study; 2. Major organ failure, renal, lung and liver failure; 3. Participants having active liver disease or unexplained persistent elevation of serum transaminases \> 3 times the upper limit of normal; 4. Participants with diabetic ketoacidosis or diabetic pre-coma; 5. Participants with a creatinine clearance \< 60mL/min; 6. History of cardiac or respiratory failure; 7. History of recent myocardial infarction; 8. Ileum, colon or stomach part or full removal rendering them unable to take the study medicines; 9. Unable to eat or keep food or medicines down or is being fed intravenously; 10. Is too frail and weak to withstand the study medicines in the opinion of the study doctor; 11. Is Unlikely to survive more than 1 month under standard of care, in the opinion of the study doctor 12. Hypersensitivity to any of the treatment drugs or excipients; 13. If the patient is on any medicines contraindicated with the study medicines (see Appendix 3); 14. Mentally incapacitated and no guardian able to sign on patients Clinical study protocol, version 5.0 METRICS TRIAL, Metabolic Cancer 001 5th Apr 2016 Confidential Page 5 of 65 behalf; 15. History or presence of alcohol or substance abuse; 16. Participation in a clinical trial of an investigational medicinal product that is viewed by the Study Physician to be a significant risk to the participant's safety; 17. Direct employee of the study site.
References
Publications (0)
Data not yet available
No reference posted for this study.